After his surprise removal from HHS’ Biomedical Advanced Research and Development Authority—a key agency partnered with pharma companies on COVID-19 drugs, vaccines and diagnostics—former Director Rick Bright is alleging whistleblower retaliation by HHS leadership. More: Ousted BARDA director pushed back on
read moreAs COVID-19 ravages across the globe, Regeneron has responded with its own two-pronged approach against the disease. One is about repurposing its arthritis med Kevzara, and the other involves a antibody cocktail aiming for clinical trials beginning next month. And
read moreCall it Libtayo’s month. After last week posting key data that could help it enter the lucrative non-small cell lung cancer market, the Sanofi and Regeneron immuno-oncology drug has rung up a win in advanced basal cell carcinoma. More: Sanofi
read moreEven a pandemic can’t slow down Seattle Genetics’ new bladder cancer treatment Padcev, which “blew out sales expectations” for the first quarter, analysts said. And now, they’re jacking up their long-term sales estimates for the drug as a result. More:
read moreNovartis and Incyte have already pitted their blockbuster JAK inhibitor Jakafi against COVID-19 as a possible treatment for a severe respiratory immune reaction. Now, seeing promise in another category of coronavirus-afflicted patients, the partners will take Jakafi into a second
read moreThe move will establish Menarini’s presence in the US biopharma market More: Menarini to buy Stemline for up to 7 million Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals